Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2025-12-31 @ 11:20 AM
Study NCT ID:
NCT00083694
Status:
COMPLETED
Last Update Posted:
2010-07-02
First Post:
2004-05-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
Sponsor:
University of Arkansas
Organization:
Study Overview
Official Title:
UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia
Status:
COMPLETED
Status Verified Date:
2010-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Detailed Description:
Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: